ANI Pharmaceuticals Inc
ANIPHealthcare|Drug Manufacturers - Specialty & Generic|USA
$82.07
-1.68 (-2.01%)
DCF (FCF)
$45.65
Tangible Book
$1.43
Graham Number
$13.56
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
1116.3,
1252.12,
1364.31,
1409,
1566.16
],
"ebit_estimate": [
292.74,
348.67,
397.66,
445.53,
488.4
],
"ebitda_estimate": [
289.9,
356.83,
410.8,
467.6,
670
],
"net_income_estimate": [
203.07,
242.29,
278.51,
308.69,
350.95
],
"per_share_eps_estimate": [
5.58,
5.32,
4.96,
6.18,
null
],
"eps_nri_estimate": [
9.41,
10.86,
12.59,
13.57,
15.21
],
"dividend_estimate": [
0.8,
0.8,
null,
null,
null
],
"book_value_per_share_estimate": [
36.06,
47.71,
60.62,
null,
null
],
"pretax_income_estimate": [
270.59,
311.58,
357.78,
386.73,
416
],
"operating_cash_flow_per_share_estimate": [
8.73,
11.11,
12.91,
17,
17
],
"roa_estimate": [
13.3,
13.6,
13.8,
null,
null
],
"roe_estimate": [
31.2,
26.2,
22.9,
null,
null
],
"gross_margin_estimate": [
60.27,
60.7,
61.1,
61.5,
59.3
],
"operating_cash_flow_estimate": [
188.08,
239.35,
278.13,
366.25,
366.25
],
"pettm_estimate": [
14.71,
15.43,
16.55,
13.28,
null
],
"long_term_growth_rate_mean": 16.69,
"long_term_revenue_growth_rate_mean": "15.24",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": 16.69,
"future_revenue_estimate_growth": 15.24,
"future_ebit_estimate_growth": 19.96,
"future_ebitda_estimate_growth": 21.54,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 19.73,
"future_pretax_income_estimate_growth": 50.6,
"future_book_value_per_share_estimate_growth": 35.72,
"future_roa_estimate_growth": 4.78,
"future_roe_estimate_growth": -12.97,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": 14.12
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
262.14,
296.73,
322.77,
263.7,
318.05,
332,
351.15
],
"ebit_estimate": [
62.64,
78.13,
88.72,
66,
100,
115,
130
],
"ebitda_estimate": [
65.07,
75.87,
92.3,
62.95,
89.25,
101.05,
115.4
],
"net_income_estimate": [
44.39,
53.91,
63.83,
42.95,
62.5,
71.25,
81.95
],
"per_share_eps_estimate": [
0.74,
1.53,
1.88,
0.3,
1.16,
1.83,
2
],
"eps_nri_estimate": [
2.01,
2.5,
2.84,
1.88,
2.69,
3.08,
3.6
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
27.38,
28.09,
30.36,
30.9,
32.33,
34.42,
36.7
],
"pretax_income_estimate": [
60.33,
72.7,
86.01,
53.9,
72.5,
81.1,
94.8
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roa_estimate": [
2.9,
3.9,
4.3,
2.3,
3.4,
4.2,
4.3
],
"roe_estimate": [
7.1,
9.3,
9.6,
5.1,
7.3,
8.6,
8.5
],
"gross_margin_estimate": [
59.85,
60.1,
60.6,
61.5,
61,
61.5,
62.5
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pettm_estimate": [
18.44,
16.85,
15.87,
15.51,
null,
null,
null
],
"long_term_growth_rate_mean": 16.69,
"long_term_revenue_growth_rate_mean": "15.24",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": 16.69,
"future_revenue_estimate_growth": 15.24,
"future_ebit_estimate_growth": 19.96,
"future_ebitda_estimate_growth": 21.54,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 19.73,
"future_pretax_income_estimate_growth": 50.6,
"future_book_value_per_share_estimate_growth": 35.72,
"future_roa_estimate_growth": 4.78,
"future_roe_estimate_growth": -12.97,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": 14.12
}